Literature DB >> 16160495

Trends in the indications for penetrating keratoplasty, 1980-2001.

Paul C Kang1, Gordon K Klintworth, Terry Kim, Alan N Carlson, Ron Adelman, Sandra Stinnett, Natalie A Afshari.   

Abstract

PURPOSE: To study the leading indications and changing trends for penetrating keratoplasty (PK) over the past 3 decades.
METHODS: This is a retrospective review of 696 cases of PK. The indications for PKs performed at the Duke University Eye Center during the years 1980-1981, 1990- 1991, and 2000-2001 were tabulated to determine trends over the past 3 decades. The main outcome measures were indications for PK.
RESULTS: During this study, 696 PKs were performed. The leading indications for PK and their respective frequencies during 1980-1981, 1990-1991, and 2000-2001 were failed grafts (10.8%, 19.0%, 27.0%, respectively), pseudophakic bullous keratopathy (PBK)/aphakic bullous keratopathy (ABK) (19.4%, 20.6%, 16.7%, respectively), Fuchs dystrophy (15.6%, 13.0%, 23.8%, respectively), keratoconus (13.4%, 8.2%, 11.8%, respectively), and corneal scar (7.0%, 8.9%, 10.7%, respectively). The number of PKs for failed grafts and Fuchs dystrophy increased over time.
CONCLUSIONS: In this study, failed graft has gradually become the leading indication for PK, whereas most other studies have reported PBK as the leading indication. Unlike many other studies, Fuchs dystrophy was a common indication for PK.

Entities:  

Mesh:

Year:  2005        PMID: 16160495     DOI: 10.1097/01.ico.0000157407.43699.22

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  26 in total

1.  Method for optical coherence elastography of the cornea.

Authors:  Matthew R Ford; William J Dupps; Andrew M Rollins; Roy A Sinha; Zhilin Hu
Journal:  J Biomed Opt       Date:  2011 Jan-Feb       Impact factor: 3.170

Review 2.  Trends in penetrating keratoplasty in the United States 1980-2005.

Authors:  Faris R Ghosheh; Federico A Cremona; Christopher J Rapuano; Elisabeth J Cohen; Brandon D Ayres; Kristin M Hammersmith; Irving M Raber; Peter R Laibson
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

Review 3.  Adult keratoplasty: has the prognosis improved in the last 25 years?

Authors:  Francis W Price; Marianne O Price
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

4.  Analysis of causes of bullous keratopathy in East China: a 10-year retrospective study.

Authors:  Xin Wang; Wentao Wang; Jianjiang Xu; Yan Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-08       Impact factor: 3.117

5.  Fuchs' corneal dystrophy.

Authors:  Allen O Eghrari; John D Gottsch
Journal:  Expert Rev Ophthalmol       Date:  2010-04

6.  Changing trends in corneal graft surgery: a ten-year review.

Authors:  Ugo de Sanctis; Camilla Alovisi; Luigi Bauchiero; Guido Caramello; Gianfranco Girotto; Claudio Panico; Luisa Vinai; Federico Genzano; Antonio Amoroso; Federico Grignolo
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

7.  Endothelial cell microRNA expression in human late-onset Fuchs' dystrophy.

Authors:  Mario Matthaei; Jianfei Hu; Laura Kallay; Charles G Eberhart; Claus Cursiefen; Jiang Qian; Eva-Maria Lackner; Albert S Jun
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-09       Impact factor: 4.799

8.  Endothelial Keratoplasty: From DLEK to DMEK.

Authors:  Mark M Fernandez; Natalie A Afshari
Journal:  Middle East Afr J Ophthalmol       Date:  2010-01

9.  Endothelial cell whole genome expression analysis in a mouse model of early-onset Fuchs' endothelial corneal dystrophy.

Authors:  Mario Matthaei; Jianfei Hu; Huan Meng; Eva-Maria Lackner; Charles G Eberhart; Jiang Qian; Haiping Hao; Albert S Jun
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-15       Impact factor: 4.799

10.  A novel VSX1 mutation identified in an individual with keratoconus in India.

Authors:  Preeti Paliwal; Anuradha Singh; Radhika Tandon; Jeevan S Titiyal; Arundhati Sharma
Journal:  Mol Vis       Date:  2009-11-28       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.